21
Hulin Bernard: Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides. Pfizer Products, Hulin Bernard, LUMB J Trevor, June 3, 2004: WO/2004/046106 (41 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, suc ...


22
Wallace John L, Cirino Giuseppe, Caliendo Giuseppe, Sparatore Anna, Santagada Vincenzo, Fiorucci Stefano: Derivatives of 4- or 5-aminosalicylic acid. Antibe Therapeutics, Wallace John L, Cirino Giuseppe, Caliendo Giuseppe, Sparatore Anna, Santagada Vincenzo, Fiorucci Stefano, BENNETT JONES, November 30, 2006: WO/2006/125293 (41 worldwide citation)

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bo ...


23
David S Garvey, Inigo Saenz de Tejada, Richard A Earl, Subhash P Khanapure: Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use. NitroMed, Hale and Dorr, December 18, 2001: US06331543 (40 worldwide citation)

The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate ...


24
Hulin Bernard, Parker Janice C: Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors. Pfizer Products, Hulin Bernard, Parker Janice C, FULLER Grover F Jr, March 3, 2005: WO/2005/019168 (40 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV ('DPP-IV')of formula (Ia) and (Ib), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are s ...


25
Jean Michel Vernier, Nicholas D P Cosford, Ian A McDonald: Substituted pyridine compounds useful as modulators of acetylcholine receptors. Merck & Co, David Rubin, David L Rose, October 14, 2003: US06632823 (39 worldwide citation)

In accordance with the present invention, a novel class of substituted pyridine compounds (optionally containing ether, ester, amide, ketone or thioether substitutions) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect compounds of the pre ...


26
Ernst Glen, Phillips Eifion, Schmiesing Richard: Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016617 (39 worldwide citation)

Nicotinic acetylcholine receptor of formula (I) wherein D, Ar1, E and Ar2 are as defined in the specification, enantiomers, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic disorde ...


27
John L Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci: Derivatives of 4- or 5-aminosalicylic acid. Antibe Therapeutics, Bennett Jones, March 22, 2011: US07910568 (38 worldwide citation)

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bo ...


28
Samuel K Yue: Method of treating myofascial pain syndrome with relaxin. January 26, 1999: US05863552 (36 worldwide citation)

A method of treating involuntary muscle dysfunctions includes administering a therapeuticaly effective amount of relaxin to a patient. Involuntary muscle dysfunctions amenable to treatment with relaxin include fibromyalgia, myofascial pain syndrome, chronic fatigue syndrome, dystonia, pelvic floor d ...


29
Ernst Glen, Phillips Eifion, Schmiesing Richard: Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016616 (36 worldwide citation)

Nicotinic acetylcholine receptor agonists of formula I wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically- acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic ...


30
Iguchi Satoru, Katsu Yasuhiro, Sone Hiroki, Uchida Chikara, Kojima Takashi: Benzimidazolone compounds having 5-ht4 receptor agonistic activity. Pfizer Japan, Pfizer, Iguchi Satoru, Katsu Yasuhiro, Sone Hiroki, Uchida Chikara, Kojima Takashi, FULLER Grover F Jr, March 10, 2005: WO/2005/021539 (36 worldwide citation)

This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, no ...



Click the thumbnails below to visualize the patent trend.